
## Susan J Semple

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/472999/publications.pdf Version: 2024-02-01



SUSAN | SEMDLE

| #  | Article  | IF         | CITATIONS |
|----|--|------------|-----------|
| 1  | Isolation and structure elucidation of caryophyllane sesquiterpenoids from leaves of Eremophila<br>spathulata. Phytochemistry Letters, 2022, 47, 156-163.  | 1.2        | 6         |
| 2  | Serrulatane diterpenoids from the leaves of Eremophila glabra and their potential as antihyperglycemic drug leads. Phytochemistry, 2022, 196, 113072.  | 2.9        | 10        |
| 3  | The Extent of Medication-Related Hospital Admissions in Australia: A Review from 1988 to 2021. Drug Safety, 2022, 45, 249-257.   | 3.2        | 32        |
| 4  | Catecholic alkaloid sulfonates and aromatic nitro compounds from Portulaca oleracea and screening of their anti-inflammatory and anti-microbial activities. Phytochemistry, 2021, 181, 112587.   | 2.9        | 10        |
| 5  | Navigating through chemical space and evolutionary time across the Australian continent in plant genus <i>Eremophila</i> . Plant Journal, 2021, 108, 555-578.  | 5.7        | 13        |
| 6  | Bioactivity-guided isolation of compounds from Sophora flavescens with antibacterial activity against Acinetobacter baumannii. Natural Product Research, 2021, , 1-9.  | 1.8        | 3         |
| 7  | Reversal of ABCC2/BCRP-Mediated Multidrug Resistance by 5,3′,5′-Trihydroxy-3,6,7,4′-Tetramethoxyflavo<br>Isolated from the Australian Desert Plant Eremophila galeata Chinnock. Biomolecules, 2021, 11, 1534.  | one<br>4.0 | 8         |
| 8  | Genotoxicity of advanced glycation end products <i>in vitro</i> is influenced by their preparation temperature, purification and cell exposure time. Mutagenesis, 2021, 36, 445-455.   | 2.6        | 1         |
| 9  | Design and synthesis of novel 4-substituted quinazoline-2-carboxamide derivatives targeting AcrB to reverse the bacterial multidrug resistance. Bioorganic Chemistry, 2020, 105, 104394.   | 4.1        | 6         |
| 10 | Antioxidant and Antiglycation Activities of Syzygium paniculatum Gaertn and Inhibition of Digestive<br>Enzymes Relevant to Type 2 Diabetes Mellitus. Plant Foods for Human Nutrition, 2020, 75, 621-627.   | 3.2        | 13        |
| 11 | Isolation, structure elucidation and PTP1B inhibitory activity of serrulatane diterpenoids from the roots of Myoporum insulare. Phytochemistry Letters, 2020, 39, 49-56.   | 1.2        | 13        |
| 12 | Antimicrobial Action and Reversal of Resistance in MRSA by Difluorobenzamide Derivatives Targeted at<br>FtsZ. Antibiotics, 2020, 9, 873.   | 3.7        | 8         |
| 13 | Can a digital slide scanner and viewing technique assist the visual scoring for the cytokinesis-block micronucleus cytome assay?. Mutagenesis, 2020, 35, 311-318.  | 2.6        | 5         |
| 14 | PTP1B-Inhibiting Branched-Chain Fatty Acid Dimers from <i>Eremophila oppositifolia</i> subsp.<br><i>angustifolia</i> Identified by High-Resolution PTP1B Inhibition Profiling and<br>HPLC-PDA-HRMS-SPE-NMR Analysis. Journal of Natural Products, 2020, 83, 1598-1610. | 3.0        | 21        |
| 15 | Phytochemistry and bioactivity of Acacia sensu stricto (Fabaceae: Mimosoideae). Phytochemistry<br>Reviews, 2019, 18, 129-172.  | 6.5        | 9         |
| 16 | Antibacterial Performance of Terpenoids from the Australian Plant Eremophila lucida. Antibiotics, 2019, 8, 63.   | 3.7        | 11        |
| 17 | Novel 5-methyl-2-phenylphenanthridium derivatives as FtsZ-targeting antibacterial agents from<br>structural simplification of natural product sanguinarine. Bioorganic and Medicinal Chemistry<br>Letters, 2018, 28, 1825-1831.  | 2.2        | 21        |
| 18 | Substitution of terminal amide with 1 H -1,2,3-triazole: Identification of unexpected class of potent antibacterial agents. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 884-891.   | 2.2        | 28        |

SUSAN J SEMPLE

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Biological activity and LC-MS/MS profiling of extracts from the Australian medicinal plant <i>Acacia<br/>ligulata</i> (Fabaceae). Natural Product Research, 2018, 32, 576-581.  | 1.8 | 5         |
| 20 | Advances in the Use of Anti-inflammatory Agents to Manage Chemotherapy-induced Oral and Gastrointestinal Mucositis. Current Pharmaceutical Design, 2018, 24, 1518-1532.   | 1.9 | 16        |
| 21 | Spatial analysis of root hemiparasitic shrubs and their hosts: a search for spatial signatures of above-<br>and below-ground interactions. Plant Ecology, 2017, 218, 185-196.   | 1.6 | 4         |
| 22 | Synthesis and antibacterial activity of 5-methylphenanthridium derivatives as FtsZ inhibitors.<br>Bioorganic and Medicinal Chemistry Letters, 2017, 27, 3399-3402.  | 2.2 | 18        |
| 23 | Design, synthesis and biological activity evaluation of novel 2,6-difluorobenzamide derivatives through FtsZ inhibition. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 958-962.   | 2.2 | 26        |
| 24 | Isolation and Structural Characterization of Echinocystic Acid Triterpenoid Saponins from the<br>Australian Medicinal and Food Plant <i>Acacia ligulata</i> . Journal of Natural Products, 2017, 80,<br>2692-2698.  | 3.0 | 15        |
| 25 | <i>In vitro</i> metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its<br>hydrolysis product by human liver microsomes and recombinant cytochrome P450 and<br>UDP-glucuronosyltransferase enzymes. Xenobiotica, 2017, 47, 461-469. | 1.1 | 1         |
| 26 | Arid awakening: new opportunities for Australian plant natural product research. Rangeland Journal,<br>2016, 38, 467.   | 0.9 | 5         |
| 27 | In vitro inhibitory activities of selected Australian medicinal plant extracts against protein glycation, angiotensin converting enzyme (ACE) and digestive enzymes linked to type II diabetes. BMC Complementary and Alternative Medicine, 2016, 16, 435.      | 3.7 | 27        |
| 28 | The extent of medication errors and adverse drug reactions throughout the patient journey in acute care in Australia. International Journal of Evidence-Based Healthcare, 2016, 14, 113-122.  | 0.5 | 106       |
| 29 | Antibacterial constituents of Eremophila alternifolia: An Australian aboriginal traditional medicinal plant. Journal of Ethnopharmacology, 2016, 182, 1-9.  | 4.1 | 21        |
| 30 | Antiproliferative Aporphine Alkaloids from Litsea glutinosa and Ethnopharmacological Relevance to<br>Kuuku l'yu Traditional Medicine. Australian Journal of Chemistry, 2016, 69, 145.   | 0.9 | 14        |
| 31 | Development and Evaluation of a Topical Anti-Inflammatory Preparation Containing Dodonaea polyandra Extract. Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18, 578.  | 2.1 | 6         |
| 32 | Serrulatane Diterpenoid fromEremophila neglectaExhibits Bacterial Biofilm Dispersion and Inhibits<br>Release of Pro-inflammatory Cytokines from Activated Macrophages. Journal of Natural Products,<br>2015, 78, 3031-3040.                                     | 3.0 | 22        |
| 33 | XPS Analysis and Antibacterial Assay of Novobiocin Coating. Procedia Chemistry, 2015, 16, 592-599.  | 0.7 | 3         |
| 34 | Polyandric Acid A, a Clerodane Diterpenoid from the Australian Medicinal Plant <i>Dodonaea<br/>polyandra,</i> Attenuates Pro-inflammatory Cytokine Secretion in Vitro and in Vivo. Journal of<br>Natural Products, 2014, 77, 85-91.                             | 3.0 | 19        |
| 35 | Traditional Australian Aboriginal medicinal plants: an untapped resource for novel therapeutic compounds?. Future Medicinal Chemistry, 2013, 5, 733-736.  | 2.3 | 41        |
| 36 | Learning from Both Sides: Experiences and Opportunities in the Investigation of Australian Aboriginal<br>Medicinal Plants. Journal of Pharmacy and Pharmaceutical Sciences, 2013, 16, 259.  | 2.1 | 12        |

SUSAN J SEMPLE

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Instability of Antibacterial Serrulatane Compounds from the Australian Plant Species Eremophila<br>duttonii. Australian Journal of Chemistry, 2012, 65, 20.  | 0.9 | 11        |
| 38 | Rare, seven-membered cyclic ether labdane diterpenoid from Dodonaea polyandra. Phytochemistry,<br>2012, 84, 141-146.   | 2.9 | 15        |
| 39 | Antibacterial spectrum and cytotoxic activities of serrulatane compounds from the Australian medicinal plant Eremophila neglecta. Journal of Applied Microbiology, 2012, 112, 197-204.                               | 3.1 | 36        |
| 40 | Ancient but New: Developing Locally Driven Enterprises Based on Traditional Medicines in Kuuku I'yu<br>Northern Kaanju Homelands, Cape York, Queensland, Australia. , 2012, , .                                      |     | 9         |
| 41 | In Vivo Activity of Benzoyl Ester Clerodane Diterpenoid Derivatives from <i>Dodonaea polyandra</i> .<br>Journal of Natural Products, 2011, 74, 650-657.  | 3.0 | 27        |
| 42 | Complementary Medicine Products Used in Autism - Evidence for Efficacy and Safety. , 2011, , .   |     | 0         |
| 43 | Flavonoids from the leaves and stems of Dodonaea polyandra: A Northern Kaanju medicinal plant.<br>Phytochemistry, 2011, 72, 1883-1888.   | 2.9 | 26        |
| 44 | Pharmaceutical care services: a systematic review of published studies, 1990 to 2003, examining<br>effectiveness in improving patient outcomes. International Journal of Pharmacy Practice, 2010, 13,<br>53-70.      | 0.6 | 84        |
| 45 | Evaluation of the anti-inflammatory properties of Dodonaea polyandra, a Kaanju traditional medicine.<br>Journal of Ethnopharmacology, 2010, 132, 340-343.  | 4.1 | 29        |
| 46 | Self-medication with over-the-counter drugs and complementary medications in South Australia's elderly population. BMC Complementary and Alternative Medicine, 2009, 9, 42.  | 3.7 | 96        |
| 47 | Complementary and alternative medicines and dietary interventions in multiple sclerosis: What is being used in South Australia and why?. Complementary Therapies in Medicine, 2009, 17, 216-223.                     | 2.7 | 80        |
| 48 | Medication safety in acute care in Australia: where are we now? Part 2: a review of strategies and<br>activities for improving medication safety 2002-2008. Australia and New Zealand Health Policy, 2009, 6,<br>24. | 2.2 | 32        |
| 49 | Medication safety in acute care in Australia: where are we now? Part 1: a review of the extent and causes of medication problems 2002–2008. Australia and New Zealand Health Policy, 2009, 6, 18.                    | 2.2 | 136       |
| 50 | Quality and availability of consumer information on heart failure in Australia. BMC Health Services<br>Research, 2008, 8, 255.   | 2.2 | 6         |
| 51 | Antimicrobial Compounds from the Australian Desert Plant <i>Eremophila neglecta</i> . Journal of<br>Natural Products, 2007, 70, 1439-1443.   | 3.0 | 51        |
| 52 | Antimicrobial activity of some Australian plant species from the genusEremophila. Journal of Basic<br>Microbiology, 2007, 47, 158-164.   | 3.3 | 31        |
| 53 | Antimicrobial compounds from Eremophila serrulata. Phytochemistry, 2007, 68, 2684-2690.  | 2.9 | 51        |
| 54 | Community pharmacists in Australia: barriers to information provision on complementary and alternative medicines. International Journal of Clinical Pharmacy, 2007, 28, 366-373.                                     | 1.4 | 62        |

SUSAN J SEMPLE

| #  | Article  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Children and autismPart 2management with complementary medicines and dietary interventions.<br>Australian Family Physician, 2007, 36, 827-30.  | 0.5 | 6         |
| 56 | Naturopaths practice behaviour: provision and access to information on complementary and alternative medicines. BMC Complementary and Alternative Medicine, 2005, 5, 15.   | 3.7 | 23        |
| 57 | Building a Safer System for Australian Health Care: Essential Role of Clinical Pharmacy Services.<br>Journal of Pharmacy Practice and Research, 2004, 34, 88-89.   | 0.8 | 1         |
| 58 | Adverse drug events and medication errors in Australia. International Journal for Quality in Health<br>Care, 2003, 15, 49i-59.   | 1.8 | 281       |
| 59 | Quality Use of Medicines in Aged-Care Facilities in Australia. Drugs and Aging, 2003, 20, 643-653.   | 2.7 | 30        |
| 60 | Antibacterial activity of Australian plant extracts against methicillin-resistant Staphylococcus<br>aureus (MRSA) and vancomycin-resistant enterococci (VRE). Journal of Basic Microbiology, 2002, 42,<br>444-448. | 3.3 | 53        |
| 61 | Antibacterial activity of traditional Australian medicinal plants. Journal of Ethnopharmacology, 2001,<br>77, 151-157.   | 4.1 | 247       |
| 62 | In vitro antiviral activity of the anthraquinone chrysophanic acid against poliovirus. Antiviral<br>Research, 2001, 49, 169-178.   | 4.1 | 134       |
| 63 | Antiviral flavonoid from Pterocaulon sphacelatum, an Australian Aboriginal medicine. Journal of<br>Ethnopharmacology, 1999, 68, 283-288.   | 4.1 | 59        |
| 64 | Screening of Australian medicinal plants for antiviral activity. Journal of Ethnopharmacology, 1998,<br>60, 163-172.   | 4.1 | 111       |
| 65 | Complementary Medicine Products Used in Autism - Evidence for Rationale. , 0, , .  |     | 0         |